DK130387D0 - Transglutaminase inhibitorer - Google Patents

Transglutaminase inhibitorer

Info

Publication number
DK130387D0
DK130387D0 DK130387A DK130387A DK130387D0 DK 130387 D0 DK130387 D0 DK 130387D0 DK 130387 A DK130387 A DK 130387A DK 130387 A DK130387 A DK 130387A DK 130387 D0 DK130387 D0 DK 130387D0
Authority
DK
Denmark
Prior art keywords
transglutaminase inhibitors
transglutaminase
inhibitors
dihydroisoxazoles
acne
Prior art date
Application number
DK130387A
Other languages
English (en)
Other versions
DK130387A (da
Inventor
Arlindo L Castelhano
Alexander Krantz
Diana H Pliura
Michael C Venuti
Lawrence M De Young
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of DK130387D0 publication Critical patent/DK130387D0/da
Publication of DK130387A publication Critical patent/DK130387A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
DK130387A 1986-03-14 1987-03-13 Transglutaminase inhibitorer DK130387A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83974386A 1986-03-14 1986-03-14

Publications (2)

Publication Number Publication Date
DK130387D0 true DK130387D0 (da) 1987-03-13
DK130387A DK130387A (da) 1987-09-15

Family

ID=25280527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK130387A DK130387A (da) 1986-03-14 1987-03-13 Transglutaminase inhibitorer

Country Status (13)

Country Link
EP (1) EP0237082B1 (da)
JP (1) JPS62252779A (da)
KR (1) KR900006545B1 (da)
AT (1) ATE63906T1 (da)
AU (1) AU599636B2 (da)
DE (1) DE3770294D1 (da)
DK (1) DK130387A (da)
ES (1) ES2038609T3 (da)
GR (1) GR3002022T3 (da)
HU (2) HU199809B (da)
IL (1) IL81887A0 (da)
NZ (1) NZ219607A (da)
ZA (1) ZA871860B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
AU691201B2 (en) * 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
KR19990067184A (ko) * 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
EP0997147B1 (en) 1997-07-08 2006-03-15 Ono Pharmaceutical Co., Ltd. Amino acid derivatives
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
WO2000004005A1 (fr) 1998-07-14 2000-01-27 Ono Pharmaceutical Co., Ltd. Derives acides amines et medicaments dont ces derives sont les principes actifs
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1232155A4 (en) 1999-11-10 2002-11-20 Smithkline Beecham Corp PROTEASE INHIBITORS
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
NZ520588A (en) 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2361993T5 (es) 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US6902781B2 (en) 2002-04-08 2005-06-07 Konica Corporation Ink-jet recording medium, silica particles and silica dispersion
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
GB0515003D0 (en) 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
BRPI0808987A2 (pt) 2007-03-16 2014-09-09 Univ Leland Stanford Junior Terapia combinatória de enzima para digestão de glúten dietético
AR067329A1 (es) * 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
WO2009067799A1 (en) * 2007-11-27 2009-06-04 The University Of Manitoba Use of transglutaminase inhibitor in skin treatment
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283403A (en) * 1976-06-14 1981-08-11 Eli Lilly And Company Substituted isoxazolines for control of plant phytopathogens
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4481190A (en) 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists

Also Published As

Publication number Publication date
GR3002022T3 (en) 1992-12-30
ES2038609T3 (es) 1993-08-01
ATE63906T1 (de) 1991-06-15
KR900006545B1 (ko) 1990-09-13
KR870008863A (ko) 1987-10-21
HUT44244A (en) 1988-02-29
AU6998787A (en) 1987-09-17
EP0237082A3 (en) 1988-09-14
ZA871860B (en) 1988-10-26
IL81887A0 (en) 1987-10-20
EP0237082A2 (en) 1987-09-16
DE3770294D1 (de) 1991-07-04
EP0237082B1 (en) 1991-05-29
NZ219607A (en) 1990-11-27
HU201032B (en) 1990-09-28
AU599636B2 (en) 1990-07-26
DK130387A (da) 1987-09-15
HU199809B (en) 1990-03-28
JPS62252779A (ja) 1987-11-04

Similar Documents

Publication Publication Date Title
DK130387A (da) Transglutaminase inhibitorer
DE69719408D1 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
NO890408D0 (no) 3-indolpyrodruesyre-derivater og deres farmasoeytiske anvendelse.
NO872589D0 (no) Noeytrale metalloendopeptidaseinhibitorer for behandling av hypertensjon.
FI895213A0 (fi) Foereningar avsedda foer vaord av alzheimers sjukdom.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE3780618T2 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
DE68907423T2 (de) Behandlung der Akne.
ES2127396T3 (es) Inhibidores aromaticos de acetilcolinesterasa.
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
DE68904462T2 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE68911776T2 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE3680881D1 (de) Behandlung von hologrammen.
DK146890D0 (da) Mercapto-acylaminosyre-antihypertensiva
FI844645L (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ATE79255T1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ATE91231T1 (de) Behandlung der akne.
DE3890823T1 (de) Anordnung von druckduesen zur behandlung von warenbahnen

Legal Events

Date Code Title Description
PUP Patent expired
AHB Application shelved due to non-payment